Amgen reported strong full-year 2022 results with significant growth in key products and successful launches, particularly in their biosimilars segment with AMGEVITA leading the U.S. market. However, the cautious 2023 guidance amidst macroeconomic challenges and potential short-term headwinds suggests a balanced outlook. Overall, the immediate stock impact is expected to be neutral.

[0]